6-May-2024
No headlines found.
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
Globe Newswire (Thu, 25-Apr 7:01 AM ET)
Globe Newswire (Wed, 24-Apr 7:01 AM ET)
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 16-Apr 4:30 PM ET)
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
Globe Newswire (Wed, 10-Apr 7:01 AM ET)
Globe Newswire (Fri, 22-Mar 7:01 AM ET)
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
Globe Newswire (Wed, 6-Mar 7:01 AM ET)
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Hookipa Pharma trades on the NASDAQ stock market under the symbol HOOK.
As of May 6, 2024, HOOK stock price declined to $0.88 with 435,776 million shares trading.
HOOK has a beta of 2.34, meaning it tends to be more sensitive to market movements. HOOK has a correlation of 0.10 to the broad based SPY ETF.
HOOK has a market cap of $87.11 million. This is considered a Micro Cap stock.
Last quarter Hookipa Pharma reported $7 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.08.
In the last 3 years, HOOK stock traded as high as $20.00 and as low as $.41.
The top ETF exchange traded funds that HOOK belongs to (by Net Assets): VTI, VXF, IWC.
HOOK stock has underperformed the market in the last year with a return of -26.6%, while SPY returned +28.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HOOK shares. However, HOOK has outperformed the market in the last 3 month and 2 week periods, returning +29.5% and +20.1%, while SPY returned +4.8% and +4.3%, respectively. This indicates HOOK has been having a stronger performance recently.
HOOK support price is $.86 and resistance is $1.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOOK stock will trade within this expected range on the day.